Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.

Chaturvedi N, Sjoelie AK, Svensson A; DIRECT Programme Study Group.

J Renin Angiotensin Aldosterone Syst. 2002 Dec;3(4):255-61.

PMID:
12584669
2.

The DIabetic REtinopathy Candesartan Trials (DIRECT) Programme: baseline characteristics.

Sjølie AK, Porta M, Parving HH, Bilous R, Klein R; DIRECT Programme Study Group.

J Renin Angiotensin Aldosterone Syst. 2005 Mar;6(1):25-32.

PMID:
16088848
3.

Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials.

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjølie AK; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1394-402. doi: 10.1016/S0140-6736(08)61412-9. Epub 2008 Sep 25.

PMID:
18823656
4.

Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group.

Lancet. 2008 Oct 18;372(9647):1385-93. doi: 10.1016/S0140-6736(08)61411-7. Epub 2008 Sep 25.

5.

Retinal microaneurysm count predicts progression and regression of diabetic retinopathy. Post-hoc results from the DIRECT Programme.

Sjølie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Aldington S, Chaturvedi N.

Diabet Med. 2011 Mar;28(3):345-51. doi: 10.1111/j.1464-5491.2010.03210.x.

PMID:
21309844
6.

The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy.

Sjølie AK, Chaturvedi N.

J Hum Hypertens. 2002 Aug;16 Suppl 3:S42-6. Review.

7.

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.

Fukui T, Rahman M, Hayashi K, Takeda K, Higaki J, Sato T, Fukushima M, Sakamoto J, Morita S, Ogihara T, Fukiyama K, Fujishima M, Saruta T; CASE-J Study Group.

Hypertens Res. 2003 Dec;26(12):979-90. Review.

8.

Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials.

Bilous R, Chaturvedi N, Sjølie AK, Fuller J, Klein R, Orchard T, Porta M, Parving HH.

Ann Intern Med. 2009 Jul 7;151(1):11-20, W3-4. Epub 2009 May 18.

PMID:
19451554
9.

Diabetic retinopathy and blockade of the renin-angiotensin system: new data from the DIRECT study programme.

Wright AD, Dodson PM.

Eye (Lond). 2010 Jan;24(1):1-6. doi: 10.1038/eye.2009.189. Epub 2009 Jul 24. Review.

PMID:
19648902
10.
11.
12.

Systematic review on urine albumin testing for early detection of diabetic complications.

Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, Hitman GA, Hawke C.

Health Technol Assess. 2005 Aug;9(30):iii-vi, xiii-163. Review.

13.

Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.

PMID:
21225239
15.

[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].

Cice G, Ferrara L, Tagliamonte E, Russo PE, Di Benedetto A, Iacono A.

Cardiologia. 1999 Dec;44(12):1071-6. Italian.

PMID:
10687258
16.

A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).

Palma Gámiz JL, Pêgo M, Contreras EM, Anglada MP, Martínez JO, Esquerra EA, Sagastagoitia Gorostiza JD; Iberian Multicenter Imidapril Study on Hypertension.

Clin Ther. 2006 Dec;28(12):2040-51.

PMID:
17296460
19.

The role of antihypertensive therapy in reducing vascular complications of type 2 diabetes. Findings from the DIabetic REtinopathy Candesartan Trials-Protect 2 study.

Tillin T, Orchard T, Malm A, Fuller J, Chaturvedi N.

J Hypertens. 2011 Jul;29(7):1457-62. doi: 10.1097/HJH.0b013e3283480db9.

PMID:
21602709
20.

[Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus].

Tsutskiridze LR, Kurashvili RB, Tsibadze AD, Kurashvili GR, Shelestova EL.

Georgian Med News. 2008 Sep;(162):54-7. Russian.

PMID:
18830032

Supplemental Content

Support Center